Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06800963 · ClinicalTrials.gov registry record · Phase 1
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
A Phase 1 study, sponsored by ImmunityBio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT06800963 is a Phase 1 study that is actively recruiting participants, run by ImmunityBio. The registered enrollment target is 40 participants.
The verdict
NCT06800963, a Phase 1 study, is actively recruiting participants, sponsored by ImmunityBio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a phase 1/2, open-label, multicenter study of intravesical Recombinant Mycobacterium Bacillus Calmette-Guérin (BCG) in participants with Non-muscle invasive bladder cancer (NMIBC) who have not received Bacillus Calmette-Guérin and have histologically confirmed presence of Carcinoma in situ (CIS) or have primary or recurrent stage Ta and/or T1 papillary tumors following Transurethral resection.
Interventions
- BIOLOGICAL Intravesical Recombinant Mycobacterium (rMBCG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-10-15 |
| Est. Completion | 2028-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06800963
The ClinicalTrials.gov registry entry for NCT06800963 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intravesical Recombinant Mycobacterium (rMBCG) is the first listed.
NCT06800963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06800963 about?
NCT06800963 is a clinical study titled "ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG". This is a phase 1/2, open-label, multicenter study of intravesical Recombinant Mycobacterium Bacillus Calmette-Guérin (BCG) in participants with Non-muscle invasive bladder cancer (NMIBC) who have not received Bacillus Calmette-Guérin and have histologically confirmed presence of Carcinoma in situ (...
What is the current status of trial NCT06800963?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-10-15. Estimated completion is 2028-02.
What interventions are being tested in trial NCT06800963?
The interventions under investigation include: Intravesical Recombinant Mycobacterium (rMBCG) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06800963?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.